Advertisement
Mayo Clinic Proceedings Home

Urine Aquaporin 1 and Perilipin 2 Differentiate Renal Carcinomas From Other Imaged Renal Masses and Bladder and Prostate Cancer

      Abstract

      Objective

      To evaluate the sensitivity and specificity of urine aquaporin 1 (AQP1) and perilipin 2 (PLIN2) concentrations to diagnose clear cell or papillary renal cell carcinoma (RCC) by comparing urine concentrations of these unique biomarkers in patients with RCC, noncancer renal masses, bladder cancer, and prostate cancer.

      Methods

      From February 1, 2012, through October 31, 2012, preoperative urine samples were obtained from patients with a presumptive diagnosis of RCC based on an imaged renal mass, prostate cancer, or transitional cell bladder cancer. Imaged renal masses were diagnosed postnephrectomy—as malignant or benign—by histology. Urine AQP1 and PLIN2 concentrations were measured by using a sensitive and specific Western blot and normalized to urine creatinine concentration.

      Results

      Median concentrations of urine AQP1 and PLIN2 in patients with clear cell and papillary RCC (n=47) were 29 and 36 relative absorbance units/mg urine creatinine, respectively. In contrast, median concentrations in patients with bladder cancer (n=22) and prostate cancer (n=27), patients with chromophobe tumors (n=7), and patients with benign renal oncocytomas (n=9) and angiomyolipomas (n=7) were all less than 10 relative absorbance units/mg urine creatinine (Kruskal-Wallis test, P<.001 vs RCC for both biomarkers) and comparable with those in healthy controls. The area under the receiver operating characteristic curve ranged from 0.99 to 1.00 for both biomarkers.

      Conclusion

      These results support the specificity and sensitivity of urine AQP1 and PLIN2 concentrations for RCC. These novel tumor-specific proteins have high clinical validity and high potential as specific screening biomarkers for clear cell and papillary RCC as well as in the differential diagnosis of imaged renal masses.

      Trial Registration

      Abbreviations and Acronyms:

      ANOVA (analysis of variance), AQP1 (aquaporin 1), PLIN2 (perilipin 2), RCC (renal cell carcinoma)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pantuck A.J.
        • Zisman A.
        • Belldegrun A.S.
        The changing natural history of renal cell carcinoma.
        J Urol. 2001; 166: 1611-1623
        • Frank I.
        • Blute M.L.
        • Cheville J.C.
        • Lohse C.M.
        • Weaver A.L.
        • Zincke H.
        Solid renal tumors: an analysis of pathological features related to tumor size.
        J Urol. 2003; 170: 2217-2220
        • Hartman D.S.
        • Choyke P.L.
        • Hartman M.S.
        From the RSNA refresher courses: a practical approach to the cystic renal mass.
        Radiographics. 2004; 24: S101-S115
        • Schachter L.R.
        • Cookson M.S.
        • Chang S.S.
        • et al.
        Second prize: frequency of benign renal cortical tumors and histologic subtypes based on size in a contemporary series: what to tell our patients.
        J Endourol. 2007; 21: 819-823
        • Duchene D.A.
        • Lotan Y.
        • Cadeddu J.A.
        • Sagalowsky A.I.
        • Koeneman K.S.
        Histopathology of surgically managed renal tumors: analysis of a contemporary series.
        Urology. 2003; 62: 827-830
        • Karakiewicz P.I.
        • Trinh Q.D.
        • Bhojani N.
        • et al.
        Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival.
        Eur Urol. 2007; 51: 1616-1624
        • Steffens S.
        • Junker K.
        • Roos F.C.
        • et al.
        Small renal cell carcinomas—how dangerous are they really? Results of a large multicenter study.
        Eur J Cancer. 2014; 50: 739-745
        • Morrissey J.J.
        • London A.N.
        • Luo J.
        • Kharasch E.D.
        Urinary biomarkers for the early diagnosis of kidney cancer.
        Mayo Clin Proc. 2010; 85: 413-421
        • Morrissey J.J.
        • Kharasch E.D.
        The specificity of urinary aquaporin 1 and perilipin 2 to screen for renal cell carcinoma.
        J Urol. 2013; 189: 1913-1920
        • Morrissey J.J.
        • Mobley J.
        • Song J.
        • et al.
        Urinary concentrations of aquaporin-1 and perilipin-2 in patients with renal cell carcinoma correlate with tumor size and stage but not grade.
        Urology. 2014; 83: 256.e9-256.e14
        • Akdogan B.
        • Gudeloglu A.
        • Inci K.
        • Gunay L.M.
        • Koni A.
        • Ozen H.
        Prevalence and predictors of benign lesions in renal masses smaller than 7 cm presumed to be renal cell carcinoma.
        Clin Genitourin Cancer. 2012; 10: 121-125
        • Halverson S.J.
        • Kunju L.P.
        • Bhalla R.
        • et al.
        Accuracy of determining small renal mass management with risk stratified biopsies: confirmation by final pathology.
        J Urol. 2013; 189: 441-446
        • Jeon H.G.
        • Lee S.R.
        • Kim K.H.
        • et al.
        Benign lesions after partial nephrectomy for presumed renal cell carcinoma in masses 4 cm or less: prevalence and predictors in Korean patients.
        Urology. 2010; 76: 574-579
        • Khan A.A.
        • Shergill I.S.
        • Quereshi S.
        • Arya M.
        • Vandal M.T.
        • Gujral S.S.
        Percutaneous needle biopsy for indeterminate renal masses: a national survey of UK consultant urologists.
        BMC Urol. 2007; 7: 10
        • Kutikov A.
        • Fossett L.K.
        • Ramchandani P.
        • et al.
        Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging.
        Urology. 2006; 68: 737-740
        • Lane B.R.
        • Samplaski M.K.
        • Herts B.R.
        • Zhou M.
        • Novick A.C.
        • Campbell S.C.
        Renal mass biopsy—a renaissance?.
        J Urol. 2008; 179: 20-27
        • Lim A.
        • O’Neil B.
        • Heilbrun M.E.
        • Dechet C.
        • Lowrance W.T.
        The contemporary role of renal mass biopsy in the management of small renal tumors.
        Front Oncol. 2012; 2: 106
        • Menogue S.R.
        • O’Brien B.A.
        • Brown A.L.
        • Cohen R.J.
        Percutaneous core biopsy of small renal mass lesions: a diagnostic tool to better stratify patients for surgical intervention.
        BJU Int. 2013; 111: E146-E151
        • Schlomer B.
        • Figenshau R.S.
        • Yan Y.
        • Venkatesh R.
        • Bhayani S.B.
        Pathological features of renal neoplasms classified by size and symptomatology.
        J Urol. 2006; 176 (discussion 1320): 1317-1320
        • Siemer S.
        • Hack M.
        • Lehmann J.
        • Becker F.
        • Stöckle M.
        Outcome of renal tumors in young adults.
        J Urol. 2006; 175 (discussion 1243-1244): 1240-1243
        • Wang R.
        • Wolf Jr., J.S.
        • Wood Jr., D.P.
        • Higgins E.J.
        • Hafez K.S.
        Accuracy of percutaneous core biopsy in management of small renal masses.
        Urology. 2009; 73 (discussion 590-591): 586-590
        • Levey A.S.
        • Bosch J.P.
        • Lewis J.B.
        • Greene T.
        • Rogers N.
        • Roth D.
        A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.
        Ann Intern Med. 1999; 130: 461-470
        • Kutikov A.
        • Uzzo R.G.
        The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth.
        J Urol. 2009; 182: 844-853
        • Cockcroft D.W.
        • Gault M.H.
        Prediction of creatinine clearance from serum creatinine.
        Nephron. 1976; 16: 31-41
        • Corcoran A.T.
        • Russo P.
        • Lowrance W.T.
        • et al.
        A review of contemporary data on surgically resected renal masses—benign or malignant?.
        Urology. 2013; 81: 707-713
        • Umbreit E.C.
        • Shimko M.S.
        • Childs M.A.
        • et al.
        Metastatic potential of a renal mass according to original tumour size at presentation.
        BJU Int. 2012; 109 (discussion 194): 190-194
        • Caoili E.M.
        • Davenport M.S.
        Role of percutaneous needle biopsy for renal masses.
        Semin Intervent Radiol. 2014; 31: 20-26
        • Leppert J.T.
        • Hanley J.
        • Wagner T.H.
        • et al.
        • Urologic Diseases in America Project
        Utilization of renal mass biopsy in patients with renal cell carcinoma.
        Urology. 2014; 83: 774-780
        • Leveridge M.J.
        • Finelli A.
        • Kachura J.R.
        • et al.
        Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy.
        Eur Urol. 2011; 60: 578-584
        • Lane B.R.
        • Kattan M.W.
        Prognostic models and algorithms in renal cell carcinoma.
        Urol Clin North Am. 2008; 35 (vii): 613-625
        • Motzer R.J.
        • Mazumdar M.
        • Bacik J.
        • Berg W.
        • Amsterdam A.
        • Ferrara J.
        Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.
        J Clin Oncol. 1999; 17: 2530-2540
        • Kerr K.F.
        • Wang Z.
        • Janes H.
        • McClelland R.L.
        • Psaty B.M.
        • Pepe M.S.
        Net reclassification indices for evaluating risk prediction instruments: a critical review.
        Epidemiology. 2014; 25: 114-121
        • Pepe M.S.
        • Feng Z.
        • Janes H.
        • Bossuyt P.M.
        • Potter J.D.
        Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design.
        J Natl Cancer Inst. 2008; 100: 1432-1438
        • Parkinson D.R.
        • McCormack R.T.
        • Keating S.M.
        • et al.
        Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer.
        Clin Cancer Res. 2014; 20: 1428-1444